← All stocks

OCULAR THERAPEUTIX, INC

OCUL Net buying
CIK 0001393434 #1892 in the set updated 17 Sep 2026
Bought (12 mo)
$461.35K
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$3.42M
$3.21M on a plan · $0.00 straight out of an exercise
Sold at will
$216.12K
4 of 29 sales
Net
−$2.96M
+$245.23K against sales at will

By person

17 insiders · 30 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Dugel Pravin
See Remarks
$1.94M (5) scheduled
−$1.94M
3,270,332
1.49%
$33.49M
+302.5%
LINDSTROM RICHARD L MD
Director
$461.35K (1)
+$461.35K
260,933
0.1188%
$2.67M
+60.4%
Saroj Namrata
Chief Business Officer
$277.79K (1) scheduled
−$277.79K
254,620
0.1159%
$2.61M
+26.4%
Heier Jeffrey S.
Chief Scientific Officer
$243.30K (5) scheduled
−$243.30K
318,326
0.1449%
$3.26M
+82.3%
Kaiser Peter
Chief Development Officer
$222.90K (5) scheduled
−$222.90K
264,378
0.1204%
$2.71M
+122.9%
Waheed Nadia
Chief Medical Officer
$220.88K (3) scheduled
−$220.88K
300,079
0.1366%
$3.07M
+111.8%
Notman Donald
Chief Operating Officer
$216.12K (4)
−$216.12K
366,529
0.1669%
$3.75M
+70.5%
Nayak Sanjay
Chief Strategy Officer
$166.41K (5) scheduled
−$166.41K
326,898
0.1488%
$3.35M
+85.5%
Anderman Todd
Chief Legal Officer
$137.37K (1) scheduled
−$137.37K
152,468
0.0694%
$1.56M
Meyers Steve Lawrence
Chief Commercial Officer
217,628
0.0991%
$2.23M
+42.5%
Robinson David Wayne
Global CCO
136,000
0.0619%
$1.39M
Warden Charles M
Director
100,464
0.0457%
$1.03M
+38.6%
Robins Jason Shand
Chief Financial Officer
68,097
0.0310%
$697.31K
+29.3%
Williams Leslie J.
Director
65,433
0.0298%
$670.03K
+74.8%
Graves Adrienne L
Director
64,000
0.0291%
$655.36K
+77.8%
RAINES MERILEE
Director
60,933
0.0277%
$623.95K
+85.0%
Hong Seung Suh
Director
60,933
0.0277%
$623.95K
+85.0%
Insider
Date
Role
Action
Shares
Price
Amount
LINDSTROM RICHARD L MD
20 Feb 2026
Director
Buy
60,229
$7.66
$461.35K

What was left out

Form 4 filings counted 48
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 25
Sales straight out of an exercise 0
Sales at will 4
Transactions with no price 0
Shares from compensation/vesting 2,704,361
History held since 8 Nov 2016